This often involves potent oncogenic functions of hypoxia-inducible factor-1α (HIF1α) (13), which orchestrates an adaptive response to acute, chronic, and cyclic hypoxia conditions in a breast cancer microenvironment (14) to confer treatment resistance and poor patient outcome (15). This evidence concerns the gene HIF1A and breast cancer.